Technical Analysis for ALRN - Aileron Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 3.65 | -1.08% | -0.04 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Buy Signal | Bullish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Doji - Bullish? | Reversal | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Earnings Movers | Other | -1.08% | |
| Outside Day | Range Expansion | -1.08% | |
| Wide Bands | Range Expansion | -1.08% | |
| Oversold Stochastic | Weakness | -1.08% |
| Alert | Time |
|---|---|
| Possible NR7 | about 13 hours ago |
| 1.5x Volume Pace | about 17 hours ago |
| Up 1% | about 17 hours ago |
| Fell Below Previous Day's Low | about 17 hours ago |
| Down 2 % | about 17 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/06/2024
Aileron Therapeutics, Inc. Description
Aileron Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation. The Company is advancing its lead oncology program to deliver efficacy and safety in a spectrum of solid and hematological malignancies. Its lead product candidate, ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers. The Company is conducting an ongoing Phase I clinical trial of ALRN-6924 in adult patients with solid tumors or lymphomas expressing non-mutated or wild-type p53 that are refractory to or intolerant of standard therapy. ALRN-6924 may reactivate p53-mediated cell death by targeting both of the natural p53 suppressor proteins, Mouse double minute 2 homolog (MDM2) and MDMX.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Biology Solid Tumors Tumor Inflammation Molecular Biology Lymphoma Cell Biology Metabolic Disease Oncogenes Peptides Hematological Malignancies Proteins P53 Tumor Suppressor Genes Treatment Of A Range Of Cancer Tumor Suppressor
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.42 |
| 52 Week Low | 1.01 |
| Average Volume | 105,454 |
| 200-Day Moving Average | 3.17 |
| 50-Day Moving Average | 5.29 |
| 20-Day Moving Average | 4.70 |
| 10-Day Moving Average | 4.25 |
| Average True Range | 0.56 |
| RSI (14) | 32.89 |
| ADX | 21.79 |
| +DI | 21.35 |
| -DI | 23.03 |
| Chandelier Exit (Long, 3 ATRs) | 5.75 |
| Chandelier Exit (Short, 3 ATRs) | 5.23 |
| Upper Bollinger Bands | 6.14 |
| Lower Bollinger Band | 3.27 |
| Percent B (%b) | 0.13 |
| BandWidth | 60.94 |
| MACD Line | -0.47 |
| MACD Signal Line | -0.34 |
| MACD Histogram | -0.1242 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.94 | ||||
| Resistance 3 (R3) | 3.95 | 3.85 | 3.89 | ||
| Resistance 2 (R2) | 3.85 | 3.78 | 3.85 | 3.88 | |
| Resistance 1 (R1) | 3.75 | 3.73 | 3.75 | 3.75 | 3.86 |
| Pivot Point | 3.66 | 3.66 | 3.65 | 3.65 | 3.66 |
| Support 1 (S1) | 3.56 | 3.58 | 3.55 | 3.55 | 3.44 |
| Support 2 (S2) | 3.46 | 3.53 | 3.46 | 3.42 | |
| Support 3 (S3) | 3.36 | 3.46 | 3.41 | ||
| Support 4 (S4) | 3.36 |
